Humanin

What is Humanin?

Humanin is a 24-amino acid peptide encoded within the mitochondrial genome. It was first discovered in 2001 during research into Alzheimer's disease and has since been studied for its broad cytoprotective effects. Humanin levels naturally decline with age, and supplementation is explored for neuroprotection, metabolic health, and longevity.

What Humanin Is Investigated For

Humanin is studied primarily as a mitochondrial-derived cytoprotective peptide with putative roles in neuroprotection (particularly against Alzheimer's pathology), insulin sensitivity, and protection against oxidative and apoptotic stress. The strongest evidence is mechanistic rather than clinical — BAX inhibition, IGFBP-3 binding, and STAT3 activation are well-characterized in cell and animal models, and observational human data show circulating Humanin declines with age and correlates with metabolic and cognitive parameters. What is essentially absent is interventional human data: no completed Phase II trials of exogenous Humanin for any indication, no established human pharmacokinetics, and no dose-ranging work. Most preclinical research uses the synthetic HNG (S14G) analog, which is ~1000-fold more potent than wild-type Humanin, so even the preclinical literature does not always translate cleanly to the 'Humanin' sold in research-chemical channels. The honest framing: interesting endogenous biology, unvalidated as a therapeutic.

History & Discovery

Humanin was first described in 2001 in two near-simultaneous publications from independent groups — Ikuo Nishimoto's laboratory in Japan, which identified it as a neuroprotective factor in a cDNA screen from surviving neurons in Alzheimer's disease brain tissue, and Yuichi Hashimoto's parallel work. The peptide's defining genomic feature emerged from follow-up work: Humanin is a 24-amino-acid peptide encoded by a short open reading frame within the mitochondrial 16S rRNA gene. This was unusual — mitochondrial DNA had been thought to encode only a small defined set of proteins, and Humanin was among the earliest examples of a functionally active peptide emerging from the mitochondrial genome's non-canonical coding capacity. Humanin became the founding member of what Pinchas Cohen's laboratory at USC later termed the mitochondrial-derived peptides (MDPs) — a family that expanded to include MOTS-c, SHLP1–6, and others. Cohen's group has driven much of the subsequent rigorous mechanistic work on Humanin, tying it to IGFBP-3 binding, BAX inhibition, STAT3 activation, and age-related decline in circulating levels. The science is legitimate and reasonably well-characterized: Humanin is a real endogenous cytoprotective peptide with identifiable receptors and pathways. What the science does not yet support is clinical translation. There are no approved indications anywhere, no completed Phase II trials for any clinical endpoint, and almost no interventional human data with exogenous Humanin. The translational distance between 'interesting mitochondrial biology' and 'therapeutic product' is significant and currently unbridged. Much of the research-chemical and wellness-channel availability of Humanin analogs (HNG, S14G-humanin) is running well ahead of what the clinical evidence supports.

How It Works

Humanin acts as a cellular guardian, protecting cells from stress and programmed death. It communicates between mitochondria and the rest of the cell, helping maintain cellular health as we age.

Humanin exerts cytoprotective effects through multiple mechanisms. It binds to IGFBP-3, modulating IGF-1 signaling. It interacts with BAX to prevent mitochondrial membrane permeabilization and apoptosis. Humanin activates the STAT3 pathway and has been shown to reduce amyloid-beta toxicity in neuronal cells. It also improves insulin sensitivity through AMPK activation and reduces inflammatory cytokine production.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Humanin:

• 01Human Phase II/III clinical trials for any indication — currently absent. The leap from well-characterized biology to clinical protocol has not been made.
• 02Human pharmacokinetics of exogenous Humanin and its analogs — absorption, distribution, clearance, and bioavailability by subcutaneous and other routes are not established.
• 03Dose-response in humans — no dose-finding studies; current forum dosing is rodent-extrapolated.
• 04Long-term safety, including cancer surveillance — the anti-apoptotic mechanism creates a specific theoretical cancer-risk question that has not been addressed by human pharmacovigilance.
• 05Efficacy of exogenous Humanin for specific endpoints (cognitive preservation, insulin sensitivity, cardiometabolic risk) in controlled human trials — not yet demonstrated.
• 06Comparative biology of Humanin versus its analogs (HNG, S14G-humanin) in humans — most preclinical work uses the analogs for potency reasons, and the extent to which wild-type Humanin produces comparable effects at achievable exogenous doses is unresolved.

Forms & Administration

Humanin analogs (such as HNG, the S14G variant) are more commonly studied due to enhanced potency and stability. Administration is typically subcutaneous injection in research settings. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Humanin and its analogs are not FDA-approved or approved in any jurisdiction for any clinical indication. They are research tools, not therapeutic products. Any use outside a registered clinical research setting is not authorized medical care.

Timeline of Effects

Common Questions

Who Humanin Is NOT For

Drug & Supplement Interactions

Clinical drug interactions for Humanin are undocumented because human pharmacology studies are absent. Theoretical interactions emerge from the known mechanisms. Humanin inhibits BAX-mediated apoptosis; concurrent use with pro-apoptotic cancer therapies (certain chemotherapeutic agents, radiation sensitizers) could in principle oppose therapeutic intent and should be avoided in oncology contexts. Humanin binds IGFBP-3 and modulates IGF-1 signaling; theoretical interactions with growth hormone therapy, IGF-1 axis drugs, and certain oncology agents targeting IGF signaling deserve clinician review. Humanin's reported insulin-sensitizing effects in preclinical models raise the theoretical possibility of additive effects with insulin, sulfonylureas, or GLP-1 agonists in diabetic patients — though clinical magnitude is unknown. The STAT3-pathway modulation introduces broad theoretical interaction surface with inflammation and immune modulation therapies, none of which has been clinically characterized. Patients on any regular medication — particularly insulin-dependent diabetics, oncology patients, and immunosuppressed individuals — should disclose Humanin use to their prescribing clinician. Combining with other peptides in longevity stacks (MOTS-c, SS-31, epithalon) is common in forum culture but has not been formally studied.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions